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Screening for Syphilis Infection in Nonpregnant Adults
and Adolescents
USPreventive Services TaskForceRecommendation Statement
US Preventive Services Task Force (USPSTF)
T he US Preventive Services Task Force (USPSTF) makesrecommendations about the effectiveness of specificpreventive care services for patients without obvious
related signs or symptoms.
It bases its recommendations on the evidence of both the
benefits and harms of the service and an assessment of the bal-
ance. The USPSTF does not consider the costs of providing a ser-
vice in this assessment.
TheUSPSTFrecognizes that clinicaldecisions involvemorecon-
siderations than evidence alone. Clinicians should understand the
evidence but individualize decision making to the specific patient
or situation. Similarly, the USPSTF notes that policy and coverage
decisions involve considerations in addition to theevidenceof clini-
cal benefits and harms.
Summary of Recommendation and Evidence
The USPSTF recommends screening for syphilis infection in per-
sons who are at increased risk for infection. (A recommendation)
(Figure 1)
See theClinical Considerations section later in this article for in-
formation on risk factors for infection.
Rationale
Importance
Thenumberof casesofprimaryandsecondarysyphilishavebeen in-
creasing since 2000. In 2014, 19 999 cases (6.3 cases per 100000
persons)ofprimaryandsecondarysyphiliswerereportedintheUnited
States.1 Left untreated, syphilis can progress to late-stage disease in
approximately 15% of persons who are infected.2 Consequences of
late-stage syphilis include development of inflammatory lesions
throughout the body (eg, aortitis, gummatous lesions, and osteitis),
which can lead to cardiovascular or organ dysfunction. Syphilis in-
fection of the central nervous system (neurosyphilis) can occur at
any stage of disease and can result in blindness, paresis, tabes dor-
salis, and dementia. Syphilis infection also increases the risk for ac-
quiring or transmitting HIV infection.
TheUSPSTFaddressesscreeningforsyphilis inpregnantwomen
in a separate recommendation statement.3
IMPORTANCE In 2014, 19 999 cases of syphilis were reported in the United States. Left
untreated, syphilis can progress to late-stage disease in about 15% of persons who are
infected. Late-stage syphilis can lead to development of inflammatory lesions throughout the
body, which can lead to cardiovascular or organ dysfunction. Syphilis infection also increases
the risk for acquiring or transmitting HIV infection.
OBJECTIVE Toupdate the2004USPreventive Services TaskForce (USPSTF) recommendation
on screening for syphilis infection innonpregnant adults. Screening for syphilis in pregnant
womenwasupdated in a separate recommendation statement in 2009 (A recommendation).
EVIDENCE REVIEW The USPSTF reviewed the evidence on screening for syphilis infection in
asymptomatic, nonpregnant adults and adolescents, including patients coinfected with other
sexually transmitted infections (such as HIV).
FINDINGS The USPSTF found convincing evidence that screening for syphilis infection in
asymptomatic, nonpregnant persons at increased risk for infection provides substantial
benefit. Accurate screening tests are available to identify syphilis infection in populations at
increased risk. Effective treatment with antibiotics can prevent progression to late-stage
disease, with small associated harms, providing an overall substantial health benefit.
CONCLUSIONS AND RECOMMENDATION The USPSTF recommends screening for syphilis
infection in persons who are at increased risk for infection. (A recommendation)
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Detection
There are numerous screening tests for syphilis. Most common is a
combinationofnontreponemal and treponemal antibody tests. The
USPSTF found convincing evidence that screening algorithmswith
high sensitivity and specificity are available to accurately detect
syphilis.
Benefits of Early Detection and Treatment
The USPSTF found convincing evidence that treatment with anti-
biotics can lead to substantial health benefits in nonpregnant per-
sonswho are at increased risk for syphilis infection by curing syphi-
lis infection, preventing manifestations of late-stage disease, and
preventing sexual transmission to others.
Harms of Early Detection and Treatment
TheUSPSTF foundnodirect evidenceon theharmsof screening for
syphilis in nonpregnant personswho are at increased risk for infec-
tion. Potential harmsof screening include false-positive results that
require clinical evaluation, unnecessary anxiety to the patient, and
the potential stigmaof having a sexually transmitted infection. The
harms of antibiotic treatment are well established, and themagni-
tude of these harms is no greater than small.
USPSTF Assessment
The USPSTF concludes with high certainty that the net benefit of
screening for syphilis infection in nonpregnant persons who are at
increased risk for infection is substantial.
Figure 1. US Preventive Services Task Force Grades and Levels of Certainty
What the USPSTF Grades Mean and Suggestions for Practice
Grade Definition
A The USPSTF recommends the service. There is high certainty that the net benefit is substantial. Offer or provide this service.
Suggestions for Practice
B The USPSTF recommends the service. There is high certainty that the net benefit is moderate, or
there is moderate certainty that the net benefit is moderate to substantial.
Offer or provide this service.
C
The USPSTF recommends selectively offering or providing this service to individual patients
based on professional judgment and patient preferences. There is at least moderate certainty
that the net benefit is small.
Offer or provide this service for selected
patients depending on individual
circumstances.
D The USPSTF recommends against the service. There is moderate or high certainty that the service
has no net benefit or that the harms outweigh the benefits.
Discourage the use of this service.
I statement
The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits
and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of
benefits and harms cannot be determined.
Read the Clinical Considerations section
of the USPSTF Recommendation
Statement. If the service is offered,
patients should understand the
uncertainty about the balance of benefits
and harms.
USPSTF Levels of Certainty Regarding Net Benefit
Level of Certainty Description
High
The available evidence usually includes consistent results from well-designed, well-conducted studies in representative primary care
populations. These studies assess the effects of the preventive service on health outcomes. This conclusion is therefore unlikely to be
strongly affected by the results of future studies.
Moderate
The available evidence is sufficient to determine the effects of the preventive service on health outcomes, but confidence in the estimate
is constrained by such factors as 
the number, size, or quality of individual studies.
inconsistency of findings across individual studies.
limited generalizability of findings to routine primary care practice.
lack of coherence in the chain of evidence.
As more information becomes available, the magnitude or direction of the observed effect could change, and this change may be large
enough to alter the conclusion.
The USPSTF defines certainty as “likelihood that the USPSTF assessment of the net benefit of a preventive service is correct.” The net benefit is defined as
benefit minus harm of the preventive service as implemented in a general, primary care population. The USPSTF assigns a certainty level based on the nature
of the overall evidence available to assess the net benefit of a preventive service.
Low
The available evidence is insufficient to assess effects on health outcomes. Evidence is insufficient because of
the limited number or size of studies.
important flaws in study design or methods.
inconsistency of findings across individual studies.
gaps in the chain of evidence.
findings not generalizable to routine primary care practice.
lack of information on important health outcomes.
More information may allow estimation of effects on health outcomes.
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Clinical Considerations
Patient Population Under Consideration
This recommendationapplies toasymptomatic,nonpregnantadults
and adolescents who are at increased risk for syphilis infection
(Figure 2). Screening for syphilis in nonpregnant populations is an
important public health approach to preventing the sexual trans-
missionof syphilis and subsequent vertical transmissionof congen-
ital syphilis.
Assessment of Risk
TheUSPSTF recommends screening for syphilis in personswhoare
at increased risk for infection.Basedon2014surveillancedata,1men
whohave sexwithmen (MSM)andmenandwomen livingwithHIV
have the highest risk for syphilis infection; 61.1% of cases of pri-
mary and secondary syphilis occurred among MSM, and approxi-
mately one-half of all MSM diagnosed with syphilis were also coin-
fected with HIV. One study found that rates of syphilis coinfection
were 5 times higher inMSM livingwithHIV comparedwithmen liv-
ingwith HIVwho do not have sexwithmen.4 Based on older study
data from northern California, the adjusted relative risk for syphilis
infection inpersons livingwithHIV (vs thosewithoutHIV)was86.0
(95%CI, 78.6-94.1); 97%of those livingwithHIV andwith incident
syphilis were male.5
When deciding which other persons to screen for syphilis,
clinicians should be aware of the prevalence of infection in the
communities they serve, as well as other sociodemographic
factors that may be associated with increased risk of syphilis
infection. Factors associated with increased prevalence that
clinicians should consider include history of incarceration, history
of commercial sex work, certain racial/ethnic groups, and being
a male younger than 29 years, as well as regional variations that
are well described. Men accounted for 90.8% of all cases of pri-
mary and secondary syphilis in 2014. Men aged 20 to 29 years
had the highest prevalence rate, nearly 3 times higher than that in
the average US male population.1 Syphilis prevalence rates are
also higher in certain racial/ethnic groups (among both men and
women); in 2014, prevalence rates of primary and secondary
syphilis were 18.9 cases per 100000 black individuals, 7.6 cases
per 100000 Hispanic individuals, 7.6 cases per 100000 Ameri-
can Indian/Alaska Native individuals, 6.5 cases per 100 000
Native Hawaiian/Pacific Islander individuals, 3.5 cases per
100 000 white individuals, and 2.8 cases per 100 000 Asian
individuals.1 The southern United States comprises the largest
proportion of syphilis cases (41%); however, the case rate is cur-
rently highest in the western United States (7.9 cases per
100000 persons). Metropolitan areas in general have increased
prevalence rates of syphilis.1 Risk factors for syphilis often do not
present independently and may frequently overlap. In addition,
local prevalence rates may change over time, so clinicians should
be aware of the latest data and trends for their specific population
and geographic area.
Although direct evidence on screening among nonpregnant
persons who are not at increased risk for syphilis infection is lack-
ing, based on the established test performance characteristics of
current screening tests and the low prevalence rate of syphilis in
this population, the yield of screening is likely low. Therefore,
screening in this population may result in high false-positive rates
and overtreatment.
Figure 2. Screening for Syphilis Infection in Nonpregnant Adults and Adolescents: Clinical Summary
Population Asymptomatic, nonpregnant adults and adolescents at increased risk for syphilis infection
Recommendation 
Screen for syphilis infection.
Grade: A
Risk Assessment 
Screening Tests 
Treatment and
Interventions
Balance of Benefits
and Harms   
Other Relevant
USPSTF
Recommendations   
For a summary of the evidence systematically reviewed in making this recommendation, the full recommendation statement, and supporting documents, please
go to http://www.uspreventiveservicestaskforce.org.   
Men who have sex with men and persons living with HIV have the highest risk for syphilis infection. Other factors that are also
associated with increased prevalence rates include a history of incarceration or commercial sex work, geography, race/ethnicity, 
and being a male younger than 29 years.
There are numerous screening tests for syphilis. The most common is a combination of nontreponemal and treponemal antibody
tests.
Syphilis infection is treated with parenteral penicillin G benzathine. Dosage and route may vary depending on the stage of disease
and patient characteristics.
The USPSTF concludes with high certainty that the net benefit of screening for syphilis infection in nonpregnant persons at
increased risk for infection is substantial.
The USPSTF has made recommendations on screening for syphilis in pregnant women, as well as screening for HIV, gonorrhea,
and chlamydia in sexually active adolescents and adults and behavioral counseling interventions to prevent sexually transmitted
infections. These recommendations are available on the USPSTF website (http://www.uspreventiveservicestaskforce.org).
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Screening Tests
Current screening tests for syphilis rely on detection of antibodies
rather than direct detection of the organism. Screening for syphilis
infection is a 2-step process involving an initial nontreponemal test
(Venereal Disease Research Laboratory [VDRL] or rapid plasma
reagin [RPR] test) followed by a confirmatory treponemal antibody
detection test (fluorescent treponemal antibody absorption
[FTA-ABS] or Treponema pallidum particle agglutination [TP-PA]
test). A reverse sequence screening algorithm has been developed
in which an automated treponemal test (such as enzyme-linked,
chemiluminescence, or multiplex flow immunoassays) is per-
formed first, followed by a nontreponemal test. If the test results
are discordant in the reverse sequence algorithm, a second trepo-
nemal test (preferably using a different treponemal antibody) is
performed.6 There is limited evidence on the accuracy of screening
using the reverse sequence algorithm. Findings from 2 studies sug-
gest that using a reverse sequence algorithmmay detect additional
cases of syphilis missed by the usual algorithm.7 However, the clini-
cal significance of these additional cases is unclear, and more stud-
ies are needed to better understand the implications of using a
reverse sequence algorithm for screening in a primary care setting.
Newer screening technologies that include rapid syphilis tests are
also currently emerging. These tests have the potential to be per-
formed in nontraditional and nonclinical settings; however, more
evidence is needed on the effectiveness of these tests as part of a
screening program in a primary care setting.
Screening Intervals
The optimal screening frequency for persons who are at increased
risk for syphilis infection is not well established.Menwho have sex
with men or persons living with HIV may benefit from more fre-
quent screening. Initial studies suggest thatdetectionof syphilis in-
fection in MSM or persons living with HIV improves when screen-
ing is performed every 3months compared with annually.7
Treatment
In its 2015 guidelines on the treatment of sexually transmitted dis-
eases, the Centers for Disease Control and Prevention (CDC) rec-
ommends parenteral penicillin G benzathine for the treatment of
syphilis. Dosage and routemay vary depending on the stage of dis-
ease and patient characteristics. To obtain themost up-to-date in-
formation, clinicians are encouraged to access the CDCwebsite.8
Additional Approaches to Prevention
Public health agencies and local health departments have a critical
role in the prevention and treatment of syphilis. Local health
departments are often responsible for investigating incident cases
of syphilis and identifying potential contacts whomay need further
testing or treatment. Primary care clinicians should be aware of
applicable local public health laws and reporting requirements for
syphilis cases.
Useful Resources
Persons who are at risk for or have been diagnosed with syphilis
infection may engage in behavior that increases their risk for
other sexually transmitted infections. TheUSPSTFhasmadeasepa-
rate recommendationonscreening for syphilis inpregnantwomen,
as well as screening for HIV, gonorrhea, and chlamydia in sexually
active adults and adolescents and behavioral counseling interven-
tions to prevent sexually transmitted infections (available at
http://www.uspreventiveservicestaskforce.org).
Other Considerations
Implementation
Although testing for syphilis in persons livingwith HIVmay be part
of HIVmanagement care provided in a specialty setting, screening
for syphilis is often conducted in primary care settings, and pri-
mary care clinicians are encouraged to routinely screen their pa-
tients who are living with HIV.
Research Needs and Gaps
Studies are needed that directly evaluate the effectiveness of
screening for syphilis on related morbidity and mortality in other
high-risk populations, in addition to MSM and persons living with
HIV, as well as studies that help identify optimal screening intervals.
Studies in adolescent populations are particularly needed. In addi-
tion, studies that evaluate the effectiveness of risk assessment
instruments or other methods to identify persons who are at
increased risk and who may benefit from screening are needed.
Further, studies on the diagnostic accuracy of reverse sequence
screening algorithms in well-defined patient populations are
needed, as well as studies on the interpretation and management
of discrepant serology results (such as a positive automated trepo-
nemal test, negative nontreponemal test, and positive second
treponemal test).
Discussion
Burden of Disease
Syphilis is a chronic, systemic infectious disease caused by the bac-
terium T pallidum. Left untreated, syphilis can progress through the
following stages: primary, secondary, latent (early and late), and
tertiary disease. Syphilis infection of the nervous system (neuro-
syphilis) can occur at any stage. Although not always present or
noticed by patients, manifestations of primary syphilis include
ulcers or a single chancre at the infection site. Manifestations of
secondary syphilis include rash, mucocutaneous lesions, and
lymphadenopathy. Manifestations of tertiary syphilis include
inflammatory lesions of the cardiovascular system (eg, aortitis
or coronary vessel disease), skin (eg, gummatous lesions), bone
(eg, osteitis), or other tissue. Rarely, other structures may be
involved. Manifestations of early neurosyphilis include cranial
nerve dysfunction, meningitis stroke, acute altered mental status,
and auditory or ophthalmic abnormalities; late neurologic manifes-
tations include tabes dorsalis and general paresis and can occur 10
to 30 years after initial infection.9 Syphilis can be sexually transmit-
ted during the early stages of infection (primary, secondary, and
early-latent syphilis); reported transmission rates range from 15.9%
to 30.3%.10,11 Congenital or vertical transmission may occur at any
stage. Syphilis infection increases the risk for acquiring or transmit-
ting HIV if exposed1; among persons living with HIV, syphilis infec-
tion is associated with a subsequent increase in HIV viral load and
decrease in CD4 cell counts.12-14
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In 2014, the total number of syphilis cases reported for all
stages (including 458 cases of congenital syphilis) and all ages
in the United States was 63 450, which is a 12.3% increase from
the previous year. The case count (19 999 cases) and case rate
(6.3 cases per 100000 persons) of primary and secondary syphilis
were the highest reported since 1994. All but 24 cases occurred in
persons 15 years and older. Among men, the rate of primary and
secondary syphilis has increased every year since 2000; however,
among women, the rate of primary and secondary syphilis has fluc-
tuated between 0.8 and 1.7 cases per 100000 since 2000. During
2013-2014, the rate among men increased 14.4%, from 10.2 to 11.7
cases per 100000; amongwomen, the rate increased 22.7%, from
0.9 to 1.1 cases per 100000.1 The majority of cases of primary and
secondary syphilis still occur among MSM. In 2014, there were
23 541 cases (7.4 cases per 100000 persons) of late and late-latent
syphilis.1 More recently, the CDC has reported an increase in cases
of ocular syphilis, with more than 200 cases reported in 20 states
since 2014, the majority of which have been among MSM living
with HIV.15
Scope of Review
The USPSTF commissioned a systematic review7,16 of studies pub-
lished since it previously reviewed the evidence on this topic in
2004.17 The USPSTF also considered evidence from its previous
evidence review. Included studies had to be applicable to the
United States, as determined by the similarity of study participants
and availability of health care services and screening tests in the
study setting. The review focused on screening for syphilis infec-
tion in asymptomatic, nonpregnant adults and adolescents, includ-
ing patients coinfected with other sexually transmitted infections
(such as HIV).
Accuracy of Screening Tests
Screening for syphilis is usually a 2-step process. A nontreponemal
test (RPRorVDRL) isperformed first, followedbya treponemal test
(TP-PA or FTA-ABS) if the first nontreponemal test result is posi-
tive. Positive results on both tests indicate past or present syphilis
infection.Estimatedsensitivitiesof theRPRandVDRLtestsare86%
and78%,respectively, fordetectingprimarysyphilis infection; 100%
fordetectingsecondarysyphilis infection; and98%and96%forde-
tecting latentsyphilis infection, respectively.7Specificity ranges from
85% to 99% andmay be reduced in persons who have a preexist-
ing condition (ie, collagen vascular disease, pregnancy, intrave-
nous drug use, advancedmalignancy, tuberculosis,malaria, or viral
andrickettsialdiseases) thatmayproducefalse-positive results.7The
TP-PA and FTA-ABS tests have a sensitivity of 88% and 84%, re-
spectively, fordetectingprimary syphilis infectionandalmost 100%
for detecting other stages and a specificity of 96% to 97%,
respectively.7
Screeningyieldusing the2-stepprocess (RPR followedby con-
firmatory FTA-ABS) can be estimated using test characteristics and
the incidence of syphilis infection in a given population. For ex-
ample, in the general population (assuming prevalence of 5 cases
per 100000persons,RPRsensitivityof91%andspecificityof95%,
and FTA-ABS sensitivity of 92%and specificity of 96%),more than
24000patientswould have to be screened to detect a single case
of syphilis infection; further, 200 per 100000 persons screened
would have false-positive results. In a high-risk population (assum-
ingprevalenceof 12%,RPRsensitivityof91%andspecificityof95%,
and FTA-ABS sensitivity of 92% and specificity of 96%), 10 pa-
tients would have to be screened to detect a single case of syphilis
infection; almost 2000per 100000persons screenedwouldhave
false-negative results.7
More recently, automated treponemal tests have been devel-
oped, including enzyme-linked, chemiluminescence, and multiplex
flow immunoassays. Reported sensitivity ranges from 64% to
100% (depending on stage of disease and type of test used), and
specificity ranges from 95.4% to 99.9%.7 These automated trepo-
nemal tests are often used in a reverse sequence screening algo-
rithm, in which an automated treponemal test is performed first,
followed by a nontreponemal test (quantitative) if the first auto-
mated treponemal test result is positive. A positive result on both
the automated treponemal and the nontreponemal test indicates
past or present syphilis infection. If the result of the automated
treponemal test is positive but the nontreponemal test result is
negative, a second treponemal test (TP-PA, FTA-ABS, or other) is
performed; a positive result on the second treponemal test indi-
cates past or present syphilis infection.6 The USPSTF reviewed 2
studies that compared a reverse sequence screening algorithm
with the traditional 2-step approach to screening.18,19 One study
was conducted in a low-prevalence US population19 and the other
in a high-prevalence metropolitan area in Canada.18 Although both
studies found that more cases were detected using the reverse
sequence algorithm, use of the reverse sequence algorithm was
associated with a higher false-positive rate. Overall, more studies
on the reverse sequence screening algorithm are needed before
definitive conclusions can bemade on its effectiveness.
Effectiveness of Early Detection and Treatment
Based on CDC data,1 MSM and persons living with HIV are at high-
est risk for syphilis infection. In 2014, the majority of cases (61.1%)
of primary and secondary syphilis occurred among MSM, and ap-
proximately one-half of all MSM diagnosed with syphilis were also
coinfectedwithHIV. Increased prevalence of syphilis infectionwas
also associated with certain racial/ethnic groups (black, Hispanic,
American Indian/AlaskaNative, andNativeHawaiian/Pacific Islander
individualshadhigherprevalence rates thanwhite individuals, rang-
ing from6.5 to 18.9 vs 3.5 cases per 100000persons), geography
(southern and western United States and metropolitan areas),
and being amale younger than 29 years.1
The USPSTF found no recent studies on the direct effective-
ness of screening for syphilis in asymptomatic, nonpregnant adults
and adolescents to reduce complications or transmission of syphilis
infection or acquisition of other sexually transmitted infections.
Older clinical trials and observational studies and almost 50 years
of clinical experience provide evidence that penicillin is effective in
the treatment of syphilis infection.9 Penicillin G has long been an
effective and accepted regimen for the treatment of all stages of
syphilis infection, and new trials are focusing on antibiotics that are
easier to administer or are alternatives for patients who are allergic
to penicillin. Data on these alternative regimens are limited.9 Given
the well-documented risk factors associated with increased preva-
lence of syphilis infection and the availability of accurate screening
tests and treatment, the USPSTF found overall that screening for
syphilis infection in persons who are at increased risk for infection
is effective.
USPSTF Recommendation: Screening for Syphilis Infection US Preventive Services Task Force Clinical Review& Education
jama.com (Reprinted) JAMA June 7, 2016 Volume 315, Number 21 2325
Downloaded From: https://jamanetwork.com/ by a University Of North Carolina - Chapel Hill User  on 08/14/2019
Copyright 2016 American Medical Association. All rights reserved.
Potential Harms of Screening and Treatment
Nostudiesdirectlyevaluatedtheharmsofscreening.Potentialharms
of screening include opportunity costs to the clinician and patient
(eg, time and resources) and false-positive results thatmay lead to
stress, labeling, and further diagnostic workup. Harms of treat-
ment include rare adverse drug-related effects, such as anaphy-
laxis due to penicillin allergy and the Jarisch-Herxheimer reaction
(febrile reaction with headache, myalgia, and other symptoms),
whichmayoccurwithin the first24hoursafter anysyphilis therapy.9
Estimate ofMagnitude of Net Benefit
Overall, the USPSTF found convincing evidence that screening for
syphilis infection in asymptomatic, nonpregnant persons who are
at increased risk for infection provides substantial benefit. Accu-
ratescreeningtestsareavailable to identifysyphilis infection inpopu-
lationsat increasedrisk.Effective treatmentwithantibioticscanpre-
ventprogression to late-stagedisease,with small associatedharms,
providing an overall substantial health benefit.
Response to Public Comment
A draft version of this recommendation statement was posted for
public comment on the USPSTF website from December 15, 2015,
to January 18, 2016. A few comments sought clarification onwhich
populations were considered to be at increased risk. The USPSTF
added language to theClinical Considerations section to clarify that
men and women living with HIV who are not MSM are considered
tobeat increased risk for syphilis. In addition,menandwomen (and
not just youngmen)whohave identified sociodemographic risk fac-
tors associated with increased prevalence rates of syphilis may be
considered at increased risk as well. In response to public com-
ments, theUSPSTFprovidedupdated surveillance data from2014.
A few comments also requested additional information on various
screening tests. However, these tests are outside the scope of this
recommendation for various reasons (eg, diagnostic tests per-
formed insymptomaticpatientsornewertechnologiesnotyetevalu-
ated for screening in a primary care setting).
Update of Previous USPSTF Recommendation
This recommendation is consistent with and updates the 2004
USPSTF recommendation. The current recommendation state-
ment includes updated information on prevalence and risk factors
in the United States and data on newer screening tests and ap-
proaches. Screening for syphilis infection inpregnantwomen isnow
addressed in a separate recommendation statement.3
Recommendations of Others
The CDC recommends at least annual screening for sexually active
MSMwith confirmatory testing for individuals with reactive serol-
ogy. Persons living with HIV should be screened at least annually;
more frequentscreeningmaybeappropriatebasedon individual risk
behaviors and local epidemiology.TheCDCalso recommendssyphi-
lis screening incorrectional facilitieson thebasisof the local areaand
institutional prevalence.9 The American Congress of Obstetricians
andGynecologists endorses the CDC’s guidelines.20 TheHIVMedi-
cineAssociation (partof the InfectiousDiseasesSocietyofAmerica)
recommends that all patients living with HIV be screened for
syphilis on initiation of care and periodically thereafter, depending
on risk.21 The American Academy of Family Physicians recom-
mends screening for syphilis infection in persons who are at in-
creased risk for infection.22
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